Int J Bipolar Disord
December 2023
Background: Lithium is an essential psychopharmaceutical, yet side effects and concerns about severe renal function impairment limit its usage.
Aims: Our objectives were to quantify the occurrence of chronic kidney disease stage 4 or higher (CKD4 +) within a lithium-treated population, using age- and time-specific cumulative incidence and age-specific lifetime risk as measures of disease occurrence. Additionally, we aimed to investigate the association between the duration of lithium treatment and the risk of CKD4 + .
Background: Modern lithium management guidelines were introduced to improve the renal prognosis of lithium patients.
Aims: To examine whether prospects for severe renal impairment (defined as chronic kidney disease at least stage 4 (CKD4)), in long-term lithium patients, have changed over time after the introduction of lithium monitoring guidelines.
Methods: The time to and hazard for CKD4 were compared between three patient cohorts who started long-term lithium in three consecutive decades: 1980s, 1990s and 2000s.
J Psychopharmacol
February 2021
Background: Little is known of the risks involved for patients who, at the start of lithium treatment, already have compromised renal function.
Aims: To assess the risk of developing severe renal impairment (chronic kidney disease (CKD) 4-5) among those patients and to explore predictors for the progression.
Methods: A retrospective longitudinal cohort study using data from Sahlgrenska University Hospital's laboratory database 1981-2017.